Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VYNE THERAPEUTICS INC.

(VYNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Insider Trends: Insider Sales Add to 90-Day Trend at VYNE Therapeutics

05/07/2021 | 05:34pm EDT


© MT Newswires 2021
All news about VYNE THERAPEUTICS INC.
07/19VYNE THERAPEUTICS : Certificate of Amendment to the Amended and Restated Certifi..
PU
07/19VYNE THERAPEUTICS INC. : Amendments to Articles of Inc. or Bylaws; Change in Fis..
AQ
07/19VYNE THERAPEUTICS : Says Austin Institute for Clinical Research Launches Study o..
MT
07/19VYNE THERAPEUTICS : Announces Initiation of Investigator Initiated Trial Evaluat..
AQ
07/19VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evalua..
CI
07/02VYNE THERAPEUTICS INC. : Other Events (form 8-K)
AQ
07/02Vyne Therapeutics Receives A Paragraph IV Certification Notice from Perrigo I..
CI
06/29VYNE Therapeutics to Participate in the 2nd Annual JAK Inhibitors Drug Develo..
GL
06/25VYNE THERAPEUTICS INC.(NASDAQGS : VYNE) dropped from Russell Microcap Value Inde..
CI
06/25VYNE THERAPEUTICS INC.(NASDAQGS : VYNE) dropped from Russell 3000 Value Index
CI
More news
Financials (USD)
Sales 2021 34,0 M - -
Net income 2021 -73,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,04x
Yield 2021 -
Capitalization 143 M 143 M -
Capi. / Sales 2021 4,21x
Capi. / Sales 2022 1,83x
Nbr of Employees 106
Free-Float 86,6%
Chart VYNE THERAPEUTICS INC.
Duration : Period :
VYNE Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VYNE THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 2,79 $
Average target price 11,43 $
Spread / Average Target 310%
EPS Revisions
Managers and Directors
David Domzalski President, Chief Executive Officer & Director
Tyler Zeronda Chief Financial Officer & Treasurer
Iain A. Stuart Chief Scientific Officer
Sharon Barbari Independent Director
Steven L. Basta Independent Director
Sector and Competitors
1st jan.Capi. (M$)
VYNE THERAPEUTICS INC.-55.85%192
GILEAD SCIENCES, INC.17.83%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.48%57 013
BIONTECH SE244.68%55 555
VERTEX PHARMACEUTICALS-17.06%50 308